{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:19:56Z","timestamp":1786378796789,"version":"build-2736575974"},"reference-count":44,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To evaluate the effect of treatment with the combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators-elexacaftor+tezacaftor+ivacaftor (ETI)-on important clinical endpoints in individuals with cystic fibrosis. Methods: This was a systematic review and meta-analysis of randomized clinical trials that compared the use of ETI in individuals with CF and at least one F508del allele with that of placebo or with an active comparator such as other combinations of CFTR modulators, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) methodology. We searched the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception to December 26th, 2022. The risk of bias was assessed using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We retrieved 54 studies in the primary search. Of these, 6 met the inclusion criteria and were analyzed (1,127 patients; 577 and 550 in the intervention and control groups, respectively). The meta-analysis revealed that the use of ETI increased FEV1% [risk difference (RD), +10.47%; 95% CI, 6.88-14.06], reduced the number of acute pulmonary exacerbations (RD, -0.16; 95% CI, -0.28 to -0.04), and improved quality of life (RD, +14.93; 95% CI, 9.98-19.89) and BMI (RD, +1.07 kg\/m2; 95% CI, 0.90-1.25). Adverse events did not differ between groups (RD, -0.03; 95% CI, -0.08 to 0.01), and none of the studies reported deaths. Conclusions: Our findings demonstrate that ETI treatment substantially improves clinically significant, patient-centered outcomes.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20230187","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:02:35Z","timestamp":1700150555000},"page":"e20230187","source":"Crossref","is-referenced-by-count":6,"title":["Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-1997","authenticated-orcid":false,"given":"Luiz","family":"Vicente Ribeiro Ferreira da Silva Filho1","sequence":"first","affiliation":[{"name":"1. Unidade de Pneumologia Pedi\u00e1trica, Instituto da Crian\u00e7a e do Adolescente, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9399-5275","authenticated-orcid":false,"given":"Rodrigo","family":"Abensur Athanazio2","sequence":"additional","affiliation":[{"name":"2. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o \u2013 InCor \u2013 Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-8588","authenticated-orcid":false,"given":"Carolina","family":"Rodrigues Tonon3","sequence":"additional","affiliation":[{"name":"3. Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Botucatu, Botucatu, (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-1384","authenticated-orcid":false,"given":"Juliana","family":"Carvalho Ferreira2","sequence":"additional","affiliation":[{"name":"2. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o \u2013 InCor \u2013 Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-2759","authenticated-orcid":false,"given":"Suzana","family":"Erico Tanni3","sequence":"additional","affiliation":[{"name":"3. Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Botucatu, Botucatu, (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. https:\/\/doi.org\/10.1038\/nrdp.2015.10","DOI":"10.1038\/nrdp.2015.10"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.O\u2019Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891-1904. https:\/\/doi.org\/10.1016\/S0140-6736(09)60327-5","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606. https:\/\/doi.org\/10.1002\/humu.10041","DOI":"10.1002\/humu.10041"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.da Silva Filho LVRF, Mar\u00f3stica PJC, Athanazio RA, Reis FJC, Damaceno N, Paes AT, et al. Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country. J Cyst Fibros. 2021;20(3):473-484. https:\/\/doi.org\/10.1016\/j.jcf.2020.08.007","DOI":"10.1016\/j.jcf.2020.08.007"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective [published correction appears in Lancet Respir Med. 2019 Dec;7(12):e40]. Lancet Respir Med. 2020;8(1):65-124. https:\/\/doi.org\/10.1016\/S2213-2600(19)30337-6","DOI":"10.1016\/s2213-2600(19)30408-4"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep. 2019;9(1):7234. https:\/\/doi.org\/10.1038\/s41598-019-43652-2","DOI":"10.1038\/s41598-019-43652-2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175-184. https:\/\/doi.org\/10.1164\/rccm.201404-0703OC","DOI":"10.1164\/rccm.201404-0703oc"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Mall MA, Mayer-Hamblett N, Rowe SM. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med. 2020;201(10):1193-1208. https:\/\/doi.org\/10.1164\/rccm.201910-1943SO","DOI":"10.1164\/rccm.201910-1943so"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Capurro V, Tomati V, Sondo E, Renda M, Borrelli A, Pastorino C, et al. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Int J Mol Sci. 2021;22(10):5262. https:\/\/doi.org\/10.3390\/ijms22105262","DOI":"10.3390\/ijms22105262"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, Bridges RJ, et al. Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences. Cell. 2012;148(1-2):164-174. https:\/\/doi.org\/10.1016\/j.cell.2011.11.023","DOI":"10.1016\/j.cell.2011.11.023"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Rabeh WM, Bossard F, Xu H, Okiyoneda T, Bagdany M, Mulvihill CM, et al. Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function. Cell. 2012;148(1-2):150-163. https:\/\/doi.org\/10.1016\/j.cell.2011.11.024","DOI":"10.1016\/j.cell.2011.11.024"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018;379(17):1612-1620. https:\/\/doi.org\/10.1056\/NEJMoa1807120","DOI":"10.1056\/nejmoa1807120"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1056\/nejmoa1908639"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2019;394(10212):1940-1948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","DOI":"10.1016\/s0140-6736(19)32597-8"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022;10(3):267-277. https:\/\/doi.org\/10.1016\/S2213-2600(21)00454-9","DOI":"10.1016\/s2213-2600(21)00454-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, et al. Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. Am J Respir Crit Care Med. 2022;206(11):1361-1369. https:\/\/doi.org\/10.1164\/rccm.202202-0392OC","DOI":"10.1164\/rccm.202202-0392oc"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.Athanazio RA, Tanni SE, Ferreira J, Dalcin PTR, Fuccio MB, Esposito C, et al. Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association). J Bras Pneumol. 2023;49(2):e20230040. https:\/\/doi.org\/10.36416\/1806-3756\/e20230040","DOI":"10.36416\/1806-3756\/e20230040"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55-61. https:\/\/doi.org\/10.1002\/jrsm.1411","DOI":"10.1002\/jrsm.1411"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.GRADEpro GDT [homepage on the Internet]. Hamilton, Canada: McMaster University and Evidence Prime; c2021. GRADEpro Guideline Development Tool [Software]. Available from: https:\/\/www.gradepro.org\/","DOI":"10.7287\/peerj.preprints.2520v1"},{"key":"ref21","unstructured":"22.Review Manager (RevMan) [Computer Program]. version 5.4. The Cochrane Collaboration, 2020."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.Barry PJ, Mall MA, \u00c1lvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021;385(9):815-825. https:\/\/doi.org\/10.1056\/NEJMoa2100665","DOI":"10.1056\/nejmoa2100665"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.Wang Y, Ma B, Li W, Li P. Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2022;13:863280. https:\/\/doi.org\/10.3389\/fphar.2022.863280","DOI":"10.3389\/fphar.2022.863280"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, et al. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018;379(17):1599-1611. https:\/\/doi.org\/10.1056\/NEJMoa1807119","DOI":"10.1056\/nejmoa1807119"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672. https:\/\/doi.org\/10.1056\/NEJMoa1105185","DOI":"10.1056\/nejmoa1105185"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.Bower JK, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A, et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study [published online ahead of print, 2023 Mar 22]. J Cyst Fibros. 2023;S1569-1993(23)00066-8. https:\/\/doi.org\/10.1016\/j.jcf.2023.03.002","DOI":"10.1016\/j.jcf.2023.03.002"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021;204(1):64-73. https:\/\/doi.org\/10.1164\/rccm.202011-4153OC","DOI":"10.1164\/rccm.202103-0796le"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-642. https:\/\/doi.org\/10.1056\/NEJM199409083311003","DOI":"10.1056\/nejm199409083311003"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. https:\/\/doi.org\/10.1001\/jama.290.13.1749","DOI":"10.1001\/jama.290.13.1749"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30. https:\/\/doi.org\/10.1056\/NEJM199901073400104","DOI":"10.1056\/nejm199901073400104"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, et al. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. Am J Respir Crit Care Med. 2018;197(6):768-775. https:\/\/doi.org\/10.1164\/rccm.201707-1541OC","DOI":"10.1164\/rccm.201707-1541oc"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.Goss CH. Acute pulmonary exacerbation in cystic fibrosis. Semin Respir Crit Care Med. 2019;40(6):792-803. https:\/\/doi.org\/10.1055\/s-0039-1697975","DOI":"10.1055\/s-0039-1697975"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.Amaral MD. Processing of CFTR: traversing the cellular maze--how much CFTR needs to go through to avoid cystic fibrosis?. Pediatr Pulmonol. 2005;39(6):479-491. https:\/\/doi.org\/10.1002\/ppul.20168","DOI":"10.1002\/ppul.20168"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.Bacalhau M, Camargo M, Magalh\u00e3es-Ghiotto GAV, Drumond S, Castelletti CHM, Lopes-Pacheco M. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals (Basel). 2023;16(3):410. https:\/\/doi.org\/10.3390\/ph16030410","DOI":"10.3390\/ph16030410"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231. https:\/\/doi.org\/10.1056\/NEJMoa1409547","DOI":"10.1056\/nejmoa1409547"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.McColley SA. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf. 2016;15(5):709-715. https:\/\/doi.org\/10.1517\/14740338.2016.1165666","DOI":"10.1517\/14740338.2016.1165666"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, et al. Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2023;208(1):59-67. https:\/\/doi.org\/10.1164\/rccm.202301-0084OC","DOI":"10.1164\/rccm.202301-0084oc"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med. 2013;1(2):148-157. https:\/\/doi.org\/10.1016\/S2213-2600(13)70026-2","DOI":"10.1016\/s2213-2600(13)70026-2"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.Greenawald L, Shenoy A, Elidemir O, Livingston F, Schaeffer D, Chidekel A. Real World Effectiveness of Ivacaftor in Pediatric Cystic Fibrosis Patients. Pediatric Pulmonology. 2018;53(S2):157. https:\/\/doi.org\/10.1002\/ppul.24152","DOI":"10.1002\/ppul.24152"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(2):188-197. https:\/\/doi.org\/10.1164\/rccm.201906-1227OC","DOI":"10.1016\/s1569-1993(19)30558-2"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.Bell SC, Mainz JG, MacGregor G, Madge S, MacEy J, Fridman M, et al. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study. BMC Pulm Med. 2019;19(1):146. https:\/\/doi.org\/10.1186\/s12890-019-0887-6","DOI":"10.1186\/s12890-019-0887-6"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.Zampoli M, Kashirskaya N, Karadag B, Filho LVRFDS, Paul GR, Noke C. Global access to affordable CFTR modulator drugs: Time for action!. J Cyst Fibros. 2022;21(3):e215-e216. https:\/\/doi.org\/10.1016\/j.jcf.2022.03.006","DOI":"10.1016\/j.jcf.2022.03.006"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.da Silva Filho LVRF, Zampoli M, Cohen-Cymberknoh M, Kabra SK. Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world. Paediatr Respir Rev. 2021;38:37-44. https:\/\/doi.org\/10.1016\/j.prrv.2020.07.004","DOI":"10.1016\/j.prrv.2020.07.004"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:03:13Z","timestamp":1700150593000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/3903\/en-US\/use-of-elexacaftor-tezacaftor-ivacaftor-in-individuals-with-cystic-fibrosis-and-at-least-one-f508del-allele--a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":44,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20230187","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}